RxDoctor Payments DataLook up a doctor →

Charles Lovell, MD

Internal Medicine · Norfolk, VANPI 1174629448

Payments from drug & device makers

$1,833,397in general payments, 2019–2025

Across 1,687 payments — averaging $1086.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$462K
  • Novartis$411K
  • AstraZeneca$338K
  • Sanofi US Services Inc.$131K
  • Merck$109K
  • Modernatx, Inc.$90K
  • plus $292K from 32 others
$12,988in research payments, 2019–2025

Across 1 payment — averaging $12,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$13K

What the payments were for

  • Consulting fees$3,04421%
  • Speaking & faculty fees$8766%
  • Travel & lodging$4,26630%
  • Food & beverage$5,97142%
  • Education$1761%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,833,397 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$66,730
Medicare patients
148
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide49$64,556
FarxigaDapagliflozin Propanediol55$55,155
OzempicSemaglutide36$49,991
XareltoRivaroxaban20$28,042
EliquisApixaban23$22,643
Colchicine28$6,328
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$5,832
Candesartan Cilexetil80$5,642
Humalog Kwikpen U-100Insulin Lispro23$5,262
Nifedipine ErNifedipine149$4,666
Colesevelam Hcl13$4,501
Chlorthalidone269$4,137
Nebivolol Hcl62$3,501
Ezetimibe121$3,461
Atorvastatin Calcium275$2,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$398$64,55649 claims
AstraZenecaFarxiga$338,328$55,15555 claims
Novo NordiskOzempic$253$49,99136 claims
Johnson & JohnsonXarelto$286$28,04220 claims
PfizerEliquis$4,012$22,64323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →